Clinical trial
A Phase 3 Safety and Efficacy Study of Vitreosolve® for Four Ophthalmic Intravitreal Injections For Inducing Posterior Vitreous Detachment in Retinopathy Patients.
NCT00908778 is registered in ClinicalTrials.gov with Vitreoretinal Technologies, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Safety and Efficacy Study of Vitreosolve® for Four Ophthalmic Intravitreal Injections For Inducing Posterior Vitreous Detachment in Retinopathy Patients.
- Lead sponsor
- Vitreoretinal Technologies, Inc.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- October 31, 2008
- Completion date
- Not reported
- Enrollment
- 160 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.